PD173074

Licensed by Pfizer Catalog No.S1264

PD173074 Chemical Structure

Molecular Weight(MW): 523.67

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Size Price Stock Quantity  
In DMSO USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331(6019), 912-6. PD173074 purchased from Selleck.

    Inhibition of FGFR signaling pathway by FGFR inhibitor PD173074 in mouse xenograft tumors. Bladder cancer SW780 cells were implanted in mice and treated with PD173074 after tumor formation as shown in B. Protein lysates of tumor tissues were prepared and immunoblotted with antibodies against phospho-ERK1/2, pan-ERK1/2, and γ-tubulin.

    Cancer Discov 2013 3(6), 636-47. PD173074 purchased from Selleck.

  • FGFR inhibitors block signaling in FGFR2-fusion-expressing cells. Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIH3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 uM BGJ398, and 0.2 and 1 uM PD173074 were immunoblotted with the relevant antibodies. β-Actin was used as a loading control.

    Hepatology 2014 59(4) ,1427-34. PD173074 purchased from Selleck.

    The level of p-FRS2 was examined in the uterine sections of Msx1f/fMsx2f/f (upper panel) and Msx1d/dMsx2d/d (lower panel) mice on day 4 of pregnancy by immunohistochemistry. Magnification: a and d: 10 x, b and e: 20 x, c and f: 40x. FGFR-specific inhibitor PD173074 was applied to one uterine horn of Msx1d/dMsx2d/d (n = 3) mice on day 3 of pregnancy. The other horn served as vehicle-treated control. Uterine horns were collected on day 4 morning and sections were subjected to immunohistochemistry to detect p-FRS2, Ki67, and Muc-1.

    PLoS Genet 2012 8(2), e1002500. PD173074 purchased from Selleck.

  • Effect of select kinase inhibitors on DF508-CFTR maturation analyzed by immunoblotting. 293MSR-GT cells stably expressing DF508-CFTR were treated with 15 uM kinase inhibitors or 0.3% DMSO (vehicle control), as indicated, grown at 37 ℃ for 48 h, and the appearance of the mature protein, band C, monitored by immunoblotting with anti-CFTR antibodies. Band B represents the immature protein. DMSO represents vehicle- alone control, 27℃ represents temperature rescue of F508-CFTR at 27℃, 37℃ represents untreated DF508-CFTR control, and WT represents WT-CFTR. Top panels depict the anti-CFTR immunoblot and bottom panels depict actin (loading) control. ** represents cellular toxicity.

    Biochem Bioph Res Co 2012 11(9), 745-57. PD173074 purchased from Selleck.

    Cells were incubated with DMSO control, 10 uM TGFBR inhibitor or 10 uM FGFR inhibitor PD173074 for 1 h. Cells were fixed, labeled with anti-GM130 (red) and analyzed by confocal microscopy. Images were analyzed using Image J (n = 3 experiments, >100 cells per condition). Scale bars, 10 uM.

    J Cell Sci 2014 10.1242/jcs.159608. PD173074 purchased from Selleck.

  • Effects of antagonists for RAGE (FPS-ZM), TLR-4 (TAK-242) and FGFR1 (PD and BGJ) on the S100B-induced alterations in glucose metabolism in L6 cells treated for 6 h. (A) Effects of FPS-ZM, (B) TAK-242 and (C) PD and BGJ on the S100B inhibition of glucose consumption.

    Am J Physiol Endocrinol Metab, 2017. PD173074 purchased from Selleck.

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEGyNlUh|ryP NHXwVIlUSU6JRWK=
KG-1 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTmTWM2OD1yLkC1NVI6KM7:TR?= MVPTRW5ITVJ?
MFM-223 M1nIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfCVYNrUUN3ME2wMlIyPTd4IN88US=> NFHYUXBUSU6JRWK=
EoL-1-cell M1LiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\j[2lEPTB;MD6zNlk5PCEQvF2= NUe5NpBLW0GQR1XS
ECC10 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwM{O4PVgh|ryP NEGyNpRUSU6JRWK=
H-EMC-SS NUjpS2xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT0WFVPUUN3ME2wMlM1PzF3IN88US=> NIOxcodUSU6JRWK=
AN3-CA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGyO21QUUN3ME2wMlQxOTN|IN88US=> MYXTRW5ITVJ?
HuO-3N1 M32yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNUS2OVMh|ryP M4fLeXNCVkeHUh?=
RT-112 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwNUS3NFEh|ryP Mm\IV2FPT0WU
NEC8 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[2Uo5xUUN3ME2wMlU3Ojh7IN88US=> NYPCTnoxW0GQR1XS
D-263MG NH73W4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPkTWM2OD1yLkexNVU6KM7:TR?= NV;HemlMW0GQR1XS
SW962 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrR[llEUUN3ME2wMlc5QTh6IN88US=> NWfvPVd3W0GQR1XS
BV-173 M2DZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vpVmlEPTB;MD64OFYzOyEQvF2= Mlz5V2FPT0WU
MFE-280 NUDSZZd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3Fell4UUN3ME2wMlg2QDd{IN88US=> MonPV2FPT0WU
HuH-7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO3Sok6UUN3ME2xMlI1PDZ2IN88US=> MnPRV2FPT0WU
RS4-11 NYjKeYlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwM{O4PFYh|ryP MmjPV2FPT0WU
DMS-114 NYrmdmIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;RT2lEPTB;MT6zOlc{PyEQvF2= NGD0NoRUSU6JRWK=
MSTO-211H NIHGd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO2TZZoUUN3ME2xMlQ4Ozd6IN88US=> NVX5RZlrW0GQR1XS
DU-145 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwNUiyNVch|ryP MlnBV2FPT0WU
A172 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwN{CzOVUh|ryP NEK1dopUSU6JRWK=
SBC-1 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwMEm0JO69VQ>? NIHCeXhUSU6JRWK=
H9 NVjGc4hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne4TWM2OD1{LkG0N|A3KM7:TR?= NHnROHZUSU6JRWK=
NCI-SNU-1 NYe4dVQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:xTWM2OD1{LkG4N|k1KM7:TR?= MUHTRW5ITVJ?
NCI-H720 NHLvUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXxTWM2OD1{LkKxNlg{KM7:TR?= NVLLeWQzW0GQR1XS
HCC2218 NY\a[mhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwM{e5N|kh|ryP NXzKZmY2W0GQR1XS
G-401 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjRfXRKSzVyPUKuOFcyQDlizszN MnX1V2FPT0WU
MPP-89 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJwNEizOlQh|ryP NFW0WmZUSU6JRWK=
697 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwNkWzN|Eh|ryP MmDXV2FPT0WU
KARPAS-45 MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljLTWM2OD1{LkewO|Q4KM7:TR?= NWPWRZc2W0GQR1XS
MG-63 M2rsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrofoxqUUN3ME2yMlk1OjZ{IN88US=> MnzOV2FPT0WU
NTERA-S-cl-D1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3viWWlEPTB;Mz6wN|Q4OiEQvF2= NH31eGRUSU6JRWK=
G-402 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNwMUK3Nlch|ryP MU\TRW5ITVJ?
NKM-1 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHNTWM2OD1|LkGzOVY1KM7:TR?= MWLTRW5ITVJ?
RH-18 NG\VRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DqT2lEPTB;Mz6xPVU6QCEQvF2= MoXqV2FPT0WU
NCI-H1092 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3hOHdGUUN3ME2zMlE6PjlizszN MV;TRW5ITVJ?
RPMI-8226 NInlfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwMkO0OFch|ryP NXvBWXNrW0GQR1XS
GAMG NHryeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNwNE[1O|Yh|ryP MUTTRW5ITVJ?
HH M2\rN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXETWM2OD1|LkS3Olc3KM7:TR?= M37QRXNCVkeHUh?=
RO82-W-1 NXTKcJZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nD[mlEPTB;Mz60PVg2PSEQvF2= NUPaOo9qW0GQR1XS
CCRF-CEM M3m2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS4Xm9KSzVyPUOuOVA1QDhizszN NX7rUYJFW0GQR1XS
NBsusSR MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzqSJhKSzVyPUOuOlM6PjlizszN M37nV3NCVkeHUh?=
CHL-1 M4flb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHrTWM2OD1|Lk[1O|k6KM7:TR?= NIrPbHBUSU6JRWK=
LK-2 NWK3ToRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zUUGlEPTB;Mz62O|E{OyEQvF2= NXeyVI8xW0GQR1XS
Hs-578-T NEHHPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXZfopuUUN3ME2zMlY4QDd|IN88US=> NX3lW201W0GQR1XS
CTB-1 NWfNPWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rHN2lEPTB;Mz64NFA2OSEQvF2= MW\TRW5ITVJ?
ES5 NW\pWItuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNwOEO2N|ch|ryP M32yPXNCVkeHUh?=
A204 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzBN5dSUUN3ME2zMlkzODd3IN88US=> MYjTRW5ITVJ?
SW780 NEPPXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn0R4lCUUN3ME2zMlkzOjR3IN88US=> M2eyb3NCVkeHUh?=
EW-3 NWXPVIZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ZTWM2OD1|Lkm4PVI{KM7:TR?= MoTCV2FPT0WU
A704 NV:3XY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPpTWM2OD12LkK4O|I{KM7:TR?= M3m1WXNCVkeHUh?=
LU-139 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfsZ3N4UUN3ME20MlMyPTN2IN88US=> MVPTRW5ITVJ?
CAL-72 MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XRcGlEPTB;ND60NVc1PiEQvF2= MVTTRW5ITVJ?
D-336MG M3PJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nYfGlEPTB;ND60OlgyPyEQvF2= M3jRfXNCVkeHUh?=
LAMA-84 NGC1UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTJRldKSzVyPUSuOVM{OSEQvF2= MWDTRW5ITVJ?
GI-ME-N M2riXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\ZRmlEPTB;ND61OFgyKM7:TR?= M3ezWnNCVkeHUh?=
KM-H2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjxTWM2OD12LkW1NlIzKM7:TR?= NGXERXpUSU6JRWK=
NCI-H209 NV\k[oY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHtcYY2UUN3ME20MlU5Ojh|IN88US=> M1TBSHNCVkeHUh?=
IGROV-1 NH2wfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LMdmlEPTB;ND64O|E3QCEQvF2= Mme5V2FPT0WU
L-363 M3zke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHYN4xKSzVyPUSuPVY3PjVizszN NF7ZSmNUSU6JRWK=
SK-MEL-3 NIPqNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3YTWM2OD13LkK0NFYh|ryP NH3RW2NUSU6JRWK=
HuO9 NIXyc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TFTmlEPTB;NT6zPFg1OyEQvF2= NXy4VFFyW0GQR1XS
NOS-1 NWjJW5lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G5VmlEPTB;NT63NlkzPyEQvF2= MonGV2FPT0WU
NCI-H1770 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XMTWlEPTB;NT65OVA{OiEQvF2= NFfySGxUSU6JRWK=
SF126 M37TV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nUWmlEPTB;Nj6yNVQxPiEQvF2= NGTCW5FUSU6JRWK=
ML-2 NYfJSIt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfEWZZKSzVyPU[uNlQ6PzdizszN M1j2PXNCVkeHUh?=
CHP-134 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\ON2dKSzVyPU[uNlUyQDJizszN NVvkfohiW0GQR1XS
NCI-H1355 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTZwNEG3N|Mh|ryP M4HjRnNCVkeHUh?=
TE-12 Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTZwN{K2O|Eh|ryP Mn\FV2FPT0WU
A4-Fuk MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTZwN{OxOFIh|ryP NU\3eG4xW0GQR1XS
MV-4-11 NUjJeXJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTkVpZKSzVyPU[uO|Y3OjZizszN MV;TRW5ITVJ?
SK-UT-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX5TWM2OD14LkmxO|g1KM7:TR?= MWrTRW5ITVJ?
J-RT3-T3-5 NXHte3lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTdwMEe3OlQh|ryP MmjzV2FPT0WU
ME-180 M3;Uc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1niemlEPTB;Nz6xNFQxPCEQvF2= NE\vXHVUSU6JRWK=
SK-MEL-28 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPk[2dKSzVyPUeuN|c5OTlizszN NHTGelNUSU6JRWK=
HAL-01 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULl[3dHUUN3ME23MlQ5OzRzIN88US=> NGn0VY1USU6JRWK=
ES8 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\RTWM2OD15Lk[5OlI3KM7:TR?= MYXTRW5ITVJ?
DB NEmwZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRThwMUG1NFQh|ryP M1XqSXNCVkeHUh?=
SK-NEP-1 Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRThwNEixOFkh|ryP NWr5NnFLW0GQR1XS
COR-L88 NYn3NGpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjZS41zUUN3ME24MlUxQThzIN88US=> Ml;JV2FPT0WU
LB1047-RCC MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j5bmlEPTB;OD61NlIyOiEQvF2= MVLTRW5ITVJ?
NCI-H520 NID3NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fpd2lEPTB;OD62NlE2PyEQvF2= MmTnV2FPT0WU
SW954 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33pWGlEPTB;OD62PVc5PiEQvF2= Mo\xV2FPT0WU
TE-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfjTWM2OD16Lke1NVQ{KM7:TR?= NFnaR4RUSU6JRWK=
D-283MED M{nUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTlwME[1N|Qh|ryP MV7TRW5ITVJ?
DBTRG-05MG MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHFXnZrUUN3ME25MlA6PjB5IN88US=> NVPsTWhVW0GQR1XS
NCI-H446 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i5d2lEPTB;OT6yPVUzPiEQvF2= MmjFV2FPT0WU
HOS MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XIO2lEPTB;OT6zOVE{PCEQvF2= NX7LS|I{W0GQR1XS
ES4 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTsTWM2OD17LkWwOVk2KM7:TR?= M3XDZ3NCVkeHUh?=
EW-13 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPsXoFKSzVyPUmuPFkxPTVizszN NUO1[441W0GQR1XS
IST-MES1 Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTlwOUS1N|Qh|ryP NF;pSWhUSU6JRWK=
CAS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTlwOUe2OVkh|ryP NXXENmJQW0GQR1XS
EM-2 NULYO2dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHGXY52UUN3ME2xNE4yOzl|IN88US=> MmfTV2FPT0WU
SW948 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj4UJpKSzVyPUGwMlE5QDJizszN NHHqT3FUSU6JRWK=
OAW-42 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvDXFl1UUN3ME2xNE42OjZ5IN88US=> M{m0UXNCVkeHUh?=
BE-13 M1HmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFyLk[1O|Yh|ryP M3HSc3NCVkeHUh?=
KU812 NWjXNIxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC4e|dKSzVyPUGwMlc{QTFizszN MmjJV2FPT0WU
SK-MEL-30 NGX0V5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXNTWM2OD1zMD64PVAyKM7:TR?= NEXL[VhUSU6JRWK=
A2780 M4PTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP3TWM2OD1zMT6wN|A5KM7:TR?= NETN[JFUSU6JRWK=
TGBC24TKB M1\5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\LTWM2OD1zMT6wO|M4KM7:TR?= NEjCZZJUSU6JRWK=
GOTO MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXMTolKSzVyPUGxMlIxQDRizszN NHTrbmFUSU6JRWK=
NCI-H526 NIn5elVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYOJJKSzVyPUGxMlM5OzdizszN M{fOWXNCVkeHUh?=
BHT-101 M{DaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2faWWlEPTB;MUGuOFQ2PiEQvF2= M1jYR3NCVkeHUh?=
NCI-H1155 NHjnPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFzLkS5OFch|ryP M37pVXNCVkeHUh?=
MCF7 M{Xsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\BV|dRUUN3ME2xNU43OTZ5IN88US=> MV;TRW5ITVJ?
MKN45 NFHXdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD6dndsUUN3ME2xNU44QTl|IN88US=> NVfaUmZnW0GQR1XS
MOLT-16 M2LHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFzLkm2PVIh|ryP MUHTRW5ITVJ?
YH-13 NVXWfJo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzlSFVVUUN3ME2xNk4xOzR4IN88US=> NYHDVYdEW0GQR1XS
P12-ICHIKAWA NY\4dXkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LSZWlEPTB;MUKuN|g1PSEQvF2= MY\TRW5ITVJ?
GR-ST NFfSOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPrUVNxUUN3ME2xNk42Ojl3IN88US=> MX7TRW5ITVJ?
CAKI-1 NH\oN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rNPWlEPTB;MUKuO|kyKM7:TR?= MUTTRW5ITVJ?
LXF-289 M17HfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fROGlEPTB;MUOuNFg{PSEQvF2= MUTTRW5ITVJ?
MHH-PREB-1 NXq3UFY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDKWlhEUUN3ME2xN{4zPzB2IN88US=> NInLbmdUSU6JRWK=
EW-16 NV;CU3ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfJTWM2OD1zMz6zNVg4KM7:TR?= NFTjPFVUSU6JRWK=
NCI-H82 M3nWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF|LkSxPVUh|ryP NFnyb4hUSU6JRWK=
MMAC-SF NWjqXHBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPCTWM2OD1zMz60OVQ4KM7:TR?= NEny[ZVUSU6JRWK=
COLO-684 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD6TWM2OD1zMz61N|E5KM7:TR?= M4\tPHNCVkeHUh?=
QIMR-WIL M{\R[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnHb4lNUUN3ME2xN{45OTB7IN88US=> MkXhV2FPT0WU
NB69 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF|Lkm4Olgh|ryP NIHG[ZBUSU6JRWK=
NCI-H2291 M36z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrUTWM2OD1zND60OFU{KM7:TR?= NYO2eFhZW0GQR1XS
MKN7 M1HXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnuc3d[UUN3ME2xOE43Pjd4IN88US=> NY\kS|AyW0GQR1XS
HDLM-2 M37vfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF3LkGyPFYh|ryP Mn\nV2FPT0WU
A253 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF3LkO4Olkh|ryP Mn7pV2FPT0WU
SK-LU-1 NHmx[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF3LkmwPVQh|ryP MVrTRW5ITVJ?
MEG-01 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TsfGlEPTB;MUWuPVExPyEQvF2= NVTC[4JQW0GQR1XS
SK-N-DZ NEnXT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF3LkmzO|Yh|ryP NGexNVJUSU6JRWK=
H4 M3qyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ztZ2lEPTB;MU[uNFg5KM7:TR?= NXnFSm16W0GQR1XS
LU-65 NYLFeYtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO5TWM2OD1zNj6zN|g1KM7:TR?= NVXzPHE1W0GQR1XS
NCI-H1048 NFTDSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r5fmlEPTB;MU[uOVE3PSEQvF2= NWj2bGN4W0GQR1XS
LCLC-97TM1 NXHBUopOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPu[YJDUUN3ME2xOk42QDh7IN88US=> NV30OopnW0GQR1XS
CAL-120 NFjO[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\oTWM2OD1zNj65PFc6KM7:TR?= NV\HUVZ4W0GQR1XS
LU-134-A MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjrNnNKSzVyPUG3MlM{QTFizszN M3P4UXNCVkeHUh?=
SK-MEL-1 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfxTWM2OD1zNz63NVI4KM7:TR?= NFnLW3RUSU6JRWK=
NCI-H69 NUfLSYV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF5LkmzNFch|ryP NXvHOGR7W0GQR1XS
MC116 NWn3fGZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X5cGlEPTB;MUeuPVc2KM7:TR?= M4nqXXNCVkeHUh?=
UMC-11 NI[w[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrEdWlKUUN3ME2xPE4yPzh6IN88US=> NYTZTYlIW0GQR1XS
HCC1395 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TjZWlEPTB;MUiuOFMxOSEQvF2= MnjmV2FPT0WU
no-10 M1fDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF6Lk[zPFgh|ryP NHS0UItUSU6JRWK=
NY MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzlTWM2OD1zOT6wPFA6KM7:TR?= M2rKWnNCVkeHUh?=
OS-RC-2 M1vPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF7LkGyOVIh|ryP MWHTRW5ITVJ?
D-423MG NHTJenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLOSZR3UUN3ME2xPU4{QTV{IN88US=> NYTYTItJW0GQR1XS
LC-2-ad MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDqTYtKSzVyPUG5Mlc3OTJizszN NFfqXVZUSU6JRWK=
DU-4475 NW\IXG9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jm[2lEPTB;MUmuPFg2OiEQvF2= NV\zUWxqW0GQR1XS
YKG-1 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DDNWlEPTB;MUmuPVYzKM7:TR?= MmHSV2FPT0WU
HCC1569 NXPuSXR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjxOZhKSzVyPUKwMlI3OjRizszN M3TG[nNCVkeHUh?=
TYK-nu NYC2NpVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJyLkK4OFch|ryP MWTTRW5ITVJ?
DEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJyLkm4NFgh|ryP MVnTRW5ITVJ?
MHH-ES-1 NUfKUZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fQdmlEPTB;MkGuN|U6PyEQvF2= MYnTRW5ITVJ?
KARPAS-299 NVfGbnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHGdGJPUUN3ME2yNU42OjlizszN NFLT[2hUSU6JRWK=
CTV-1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJzLk[xO|Ih|ryP M1zWenNCVkeHUh?=
NCI-H2452 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPFemVKSzVyPUKyMlY3PzdizszN MmTvV2FPT0WU
D-566MG NEDrR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTXNm5KSzVyPUKyMlc3ODFizszN MXPTRW5ITVJ?
EFO-27 MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTrV3ZRUUN3ME2yN{4xPjVzIN88US=> NInCbXpUSU6JRWK=
NCI-H596 NVHYVppKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ|Lki1Nlch|ryP NXnFTo11W0GQR1XS
KS-1 M1G5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P3TGlEPTB;MkSuNlc2QSEQvF2= NVvuflc6W0GQR1XS
8305C Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfCTlBUUUN3ME2yOE41ODR3IN88US=> MmT2V2FPT0WU
A427 NHPyfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LoSGlEPTB;MkWuNFMzOyEQvF2= M{HzRnNCVkeHUh?=
COLO-800 M4LId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPydphjUUN3ME2yOU4yODZzIN88US=> NH;q[2tUSU6JRWK=
SJRH30 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\lcJhKSzVyPUK1MlM6ODhizszN NWGyUFJIW0GQR1XS
MEL-HO MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ3LkSzNVkh|ryP M32xPXNCVkeHUh?=
FTC-133 M2HUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJ3LkixPFYh|ryP NVrIUGM{W0GQR1XS
SF295 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13PWGlEPTB;Mk[uNlk3KM7:TR?= MVPTRW5ITVJ?
SW1710 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLwcZkxUUN3ME2yOk41OTJ|IN88US=> MonNV2FPT0WU
EFM-19 NUHlfHhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj6bmtxUUN3ME2yOk45OTR3IN88US=> MUHTRW5ITVJ?
NB10 NX75c4FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\xTWM2OD1{OD6yNlk4KM7:TR?= MlrGV2FPT0WU
TK10 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInWXGlKSzVyPUK4MlI{QTlizszN M1\VTXNCVkeHUh?=
D-502MG NXnjOG1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3hTWM2OD1{OD60JO69VQ>? NVjpVnRiW0GQR1XS
EW-18 M{nKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJ6LkSzPFYh|ryP NF70TZRUSU6JRWK=
VMRC-RCZ M3S1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33o[GlEPTB;MkiuPVQyKM7:TR?= MoDEV2FPT0WU
Ca9-22 NGDPeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHqTWM2OD1{OT60OVU4KM7:TR?= NH32V25USU6JRWK=
KYSE-70 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ7LkW3PFYh|ryP MWTTRW5ITVJ?
A101D M{PO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XGd2lEPTB;MkmuOlQ4OiEQvF2= MkjGV2FPT0WU
WM-115 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHGUGF4UUN3ME2yPU44PjB5IN88US=> MkTaV2FPT0WU
HCC2157 M3\UcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\3ZlJKSzVyPUK5Mlg5ODdizszN M3;PWnNCVkeHUh?=
TE-9 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrOR2xKSzVyPUK5Mlg5PjVizszN NUjobJRRW0GQR1XS
K-562 NWHtcVlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTtTGhKSzVyPUOwMlA6OzNizszN NITaUZZUSU6JRWK=
SN12C MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfjTWM2OD1|MD6xOFI3KM7:TR?= NX3m[ldWW0GQR1XS
ESS-1 NGLpRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2wcJJKSzVyPUOwMlQ4PTlizszN NUjzcZdXW0GQR1XS
K5 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNyLke2OEDPxE1? NGC1S4VUSU6JRWK=
J82 NVq3c3o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHQZ2lKSzVyPUOxMlA5QTdizszN Mln5V2FPT0WU
HOP-92 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq4UVZLUUN3ME2zNU4yOTFzIN88US=> NWq5V|VPW0GQR1XS
NCI-H2228 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNzLkOyPVYh|ryP Mn65V2FPT0WU
OCI-AML2 NFPuWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq1TWM2OD1|MT6zOlEh|ryP NH\4[lVUSU6JRWK=
NCI-SNU-5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfrTWM2OD1|MT64NVM4KM7:TR?= NYPmNWdUW0GQR1XS
A3-KAW NVvjNm9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfUclg{UUN3ME2zNU46OjR|IN88US=> Mo\vV2FPT0WU
LCLC-103H MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN{LkCxO|Eh|ryP Mm\SV2FPT0WU
KY821 M320cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTRTIsxUUN3ME2zNk43QDh2IN88US=> M4\rbXNCVkeHUh?=
JVM-2 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkniTWM2OD1|Mj65NFc6KM7:TR?= MXTTRW5ITVJ?
Mo-T NIPlN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPFTWM2OD1|Mz6xNFA2KM7:TR?= M1LycnNCVkeHUh?=
IA-LM NX;vSWdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfWTWM2OD1|Mz6yO|Uh|ryP MVnTRW5ITVJ?
C8166 NELoNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XtN2lEPTB;M{OuN|E6OiEQvF2= M1ji[XNCVkeHUh?=
TCCSUP NHjQb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHQbZpKSzVyPUOzMlQ{ODdizszN NHLQXY9USU6JRWK=
JEG-3 NVPsR2wzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq1NZVCUUN3ME2zN{41PzZ6IN88US=> MW\TRW5ITVJ?
MS-1 MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvuTWM2OD1|Mz61OVUyKM7:TR?= M3rsb3NCVkeHUh?=
NCI-H1304 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTafXlKSzVyPUOzMlU4OjVizszN M{TPUHNCVkeHUh?=
Ramos-2G6-4C10 NHznU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7jNVVKSzVyPUO0MlA{OzVizszN NXXC[IdRW0GQR1XS
MDA-MB-453 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ZTWM2OD1|ND62N|k2KM7:TR?= M3mz[3NCVkeHUh?=
KYSE-520 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jVOWlEPTB;M{SuO|E5OSEQvF2= MlnSV2FPT0WU
SW900 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlryTWM2OD1|ND64NVE2KM7:TR?= MmO1V2FPT0WU
HCC2998 M4nmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTN3LkG1Nlkh|ryP M4rtZ3NCVkeHUh?=
A2058 M3OxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXtV|k5UUN3ME2zOU43ODZzIN88US=> Mn[wV2FPT0WU
OVCAR-3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jzN2lEPTB;M{[uNlA1PSEQvF2= Mk[1V2FPT0WU
MOLT-4 NHvwcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLrNVJKSzVyPUO2MlIzQTRizszN MkG1V2FPT0WU
CAPAN-1 NEOxUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:wT3lTUUN3ME2zOk41Pjl7IN88US=> NFX2[IlUSU6JRWK=
SCC-9 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jve2lEPTB;M{euOFAzPyEQvF2= NXzER5p3W0GQR1XS
SF268 NEO0cG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrwOZFVUUN3ME2zPE4{PDN|IN88US=> NIPJNJJUSU6JRWK=
HGC-27 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTN6LkO3NVEh|ryP MoPCV2FPT0WU
DOHH-2 M1zxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i3UmlEPTB;M{iuO|E2QCEQvF2= NYPpcWZzW0GQR1XS
KE-37 M1r0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN6Lkm4Nlgh|ryP MnLjV2FPT0WU
MOLT-13 NEHSUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnG[Y9PUUN3ME2zPU4zPTB{IN88US=> NWXWSYdXW0GQR1XS
ES1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN7LkO4OUDPxE1? M1u4fnNCVkeHUh?=
SK-OV-3 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHmxbVlKSzVyPUO5Mlk3PDNizszN NInYRWZUSU6JRWK=
SNU-449 NGfmNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfyTWM2OD12MD6wO|Y1KM7:TR?= M1exN3NCVkeHUh?=
KYSE-510 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLsTWM2OD12MD6xNlk2KM7:TR?= NVywVHBLW0GQR1XS
HL-60 M{D3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPpfmJyUUN3ME20NE46Pzh|IN88US=> NXzWVHlKW0GQR1XS
DJM-1 NFfRdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3jTWM2OD12MD65O|k6KM7:TR?= M1PmbXNCVkeHUh?=
TGBC11TKB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;UbWlEPTB;NEGuNFkzPiEQvF2= NWW0cWVpW0GQR1XS
U-2-OS NI[5ZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTR{LkK2OFEh|ryP M2HSN3NCVkeHUh?=
NCI-H2030 NXzQcVdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LXc2lEPTB;NEKuOFM3QCEQvF2= NIjxOXRUSU6JRWK=
LU-135 M3XJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnVTWM2OD12Mj61OFQ4KM7:TR?= MYnTRW5ITVJ?
ZR-75-30 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jVd2lEPTB;NEOuNFQ6OyEQvF2= MnHWV2FPT0WU
GT3TKB NFy0e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHJdlhKSzVyPUSzMlI3PzlizszN MkfkV2FPT0WU
RPMI-2650 NYmwSWg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjweoVzUUN3ME20N{44QDF4IN88US=> NYTOeXluW0GQR1XS
SAS MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHqVohrUUN3ME20N{46PTN2IN88US=> M17VeHNCVkeHUh?=
MDA-MB-231 M1XDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7lTWM2OD12Mz65OlA6KM7:TR?= MYXTRW5ITVJ?
JVM-3 M3HFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIWwW3lKSzVyPUS0MlA2OzNizszN M1LY[XNCVkeHUh?=
COLO-320-HSR MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[0UJpGUUN3ME20OE42PjN|IN88US=> NIL1XWtUSU6JRWK=
SNB75 NUnqNIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTR2Lk[xNFUh|ryP MYHTRW5ITVJ?
NCI-H441 NIPNTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTR2LkmzNlgh|ryP M2r0SXNCVkeHUh?=
HCT-116 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq5[Y9KSzVyPUS0Mlk5PjhizszN MnfiV2FPT0WU
NCI-H226 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTR3Lk[zOlgh|ryP NX7YNY57W0GQR1XS
CAL-33 NFnPUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\xVppKSzVyPUS1MlkzOTdizszN M4rRWnNCVkeHUh?=
NCI-H1437 NGT5bGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7lWmduUUN3ME20Ok4{OjFizszN MmD0V2FPT0WU
HCC1187 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH6NG9KSzVyPUS2MlQzPTVizszN NHvGO2RUSU6JRWK=
NUGC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rPR2lEPTB;NE[uOVcxQSEQvF2= MmrLV2FPT0WU
T98G MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTR5LkW0O{DPxE1? NVHFV4syW0GQR1XS
OVCAR-8 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP2ZZFKSzVyPUS3MlY5OyEQvF2= MV\TRW5ITVJ?
LB2241-RCC NYrLWYlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTR5LkeyO{DPxE1? MXrTRW5ITVJ?
NCI-H358 NWjacIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;hd2lEPTB;NEiuNVE2OiEQvF2= MmHsV2FPT0WU
PANC-08-13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTZTWM2OD12OD6xPFU{KM7:TR?= MnvwV2FPT0WU
KP-N-YN NY\OOnRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIezdoRKSzVyPUS4MlIyODJizszN NXHRb497W0GQR1XS
NCI-H1755 NVHKW5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfVO4hKSzVyPUS4MlI4OjZizszN M2TGRnNCVkeHUh?=
NCI-N87 NIH0SoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS4[|U{UUN3ME20PE4zQTlzIN88US=> NGPQSmdUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]

Protocol

Kinase Assay:[1]
+ Expand

In vitro kinase inhibition assays:

Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:[4]
+ Expand
  • Cell lines: KMS11 and KMS18
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 48 hours
  • Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Swiss Webster mice with induced corneal angiogenesis
  • Formulation: Prepared in sterile fashion
  • Dosages: ~2 mg/kg/day
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the half-life of PD173074(S1264) in vivo?

  • Answer:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID